Lupin Pharmaceuticals’ smooth-run in Japan; all eyes on biosimilars growth

which would come from biosimilars and it expects nearly 50 per cent of its Japan sales to come from the speciality business. Lupin’s Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit.
( read original story …)


Related Post

Weigh Anchor: Historic brewing company is sold to ...
views 265
Reports put the sale price at $85 million, but nei...
Nikkei 225 Beats Topix by Most in 20 Years on `Abn...
views 58
In Japanese equities, a gauge of the country’s big...
Japan pledges 300 bil. yen economic package at Abe...
views 300
where Abe said they discussed a long-standing row ...
Irasshaimase* Japan! W Hotels Scheduled To Debut I...
views 177
"In 2020, Japan will capture the global spotlight ...
Rollercoaster riders left dangling upside down for...
views 120
It was an amusement park-goer’s worst nightmare. M...
Japan shares higher at close of trade; Nikkei 225 ...
views 165
Investing.com – Japan equities were higher at the ...
Climbing centre breaks ground on Olympic-calibre f...
views 338
The sport has been officially added to the list fo...
Naomi Osaka on firing coach: Wants to be around pe...
views 17
Naomi Osaka fired coach Sascha Bajin last week, tw...
India, Japan to introduce AI, robotics in defence ...
views 172
Japan's intention is to start this quickly ... But...
An Identity Lost in Post-War Japan Took 67 Years t...
views 278
At a public bath in a Yokohama slum in the 1950s, ...